A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

NCT06646276 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

530

Enrollment

INDUSTRY

Sponsor class

Conditions

Extensive-Stage Small Cell Lung Cancer

Interventions

BIOLOGICAL: BMS-986489 (BMS-986012+Nivolumab)
BIOLOGICAL: Atezolizumab
DRUG: Carboplatin
DRUG: Etoposide

Sponsor

Bristol-Myers Squibb